By Fineline Cube Changchun High-Tech Industries (Group) Co., Ltd. (SHE: 000661) announced that its subsidiary GenSci has initiated an overseas Phase II clinical trial for Graves’ disease (GD) with or without thyroid eye disease (TED) using its first out-licensed pipeline asset, GenSci098 (YB-101). The first patient has been successfully dosed in the study, which is being conducted by GenSci’s US partner Yarrow Bioscience, Inc. (NASDAQ: YARW).
Clinical Development Overview
| Item | Detail |
|---|---|
| Sponsor | Yarrow Bioscience, Inc. (NASDAQ: YARW) |
| Drug Candidate | GenSci098 (YB-101) |
| Indication | Graves’ disease (GD) with or without thyroid eye disease (TED) |
| Trial Design | Randomized, blinded, placebo-controlled Phase 2a/2b study |
| Milestone | First patient dosed |
| Data Readout | Phase 2a proof-of-concept data expected H2 2027 |
| Licensing Agreement | Exclusive overseas rights granted to Yarrow Bio in December 2025 |
Drug Profile & Mechanism of Action
- Molecule Type: Humanized thyroid-stimulating hormone receptor (TSHR) monoclonal antibody
- Development Origin: Independently developed by GenSci with global intellectual property
- Therapeutic Approach: Etiology-targeted therapy that specifically blocks binding of pathogenic antibodies to TSHR
- Mechanism: Suppresses downstream signal transduction pathways responsible for GD and TED pathogenesis
- Administration: Convenient, low-frequency subcutaneous injection regimen
- Differentiation: Potential to treat both GD and TED simultaneously with a single targeted agent
Strategic Partnership Details
The collaboration represents GenSci’s first international out-licensing deal, marking a significant milestone in Changchun High-Tech’s global expansion strategy. Under the December 2025 agreement, Yarrow Bioscience secured exclusive overseas development and commercialization rights to GenSci098, while GenSci retains all rights in Greater China.
This partnership leverages Yarrow’s expertise in autoimmune disease development and US regulatory experience, while providing GenSci with non-dilutive funding and global validation of its innovative TSHR-targeting platform.
Market Opportunity & Competitive Landscape
- Patient Population: Graves’ disease affects approximately 1% of the global population, with 25-50% of patients developing TED
- Current Treatment Gap: Existing therapies primarily address symptoms rather than underlying etiology, with limited options for TED
- Competitive Advantage: GenSci098’s dual indication potential and convenient administration profile could capture significant market share in the autoimmune thyroid disorder segment
- Revenue Potential: Successful development could generate substantial milestone payments and royalty revenue for Changchun High-Tech from international markets
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and commercial expectations. Actual results may differ due to clinical trial outcomes, regulatory decisions, competitive developments, and market conditions.-Fineline Info & Tech